Cargando…
Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction: A Secondary Analysis of the TOPCAT Trial
IMPORTANCE: β-Blockers are prescribed to most patients with heart failure (HF) with a preserved ejection fraction (HFpEF), but their effect on HFpEF remains unclear. OBJECTIVE: To determine the association of β-blocker use with HF hospitalizations and cardiovascular disease (CVD) mortality, overall...
Autores principales: | Silverman, Daniel N., Plante, Timothy B., Infeld, Margaret, Callas, Peter W., Juraschek, Stephen P., Dougherty, Geoff B., Meyer, Markus |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902757/ https://www.ncbi.nlm.nih.gov/pubmed/31800067 http://dx.doi.org/10.1001/jamanetworkopen.2019.16598 |
Ejemplares similares
-
Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT
por: Dong, Bin, et al.
Publicado: (2020) -
Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022) -
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial
por: De Marco, Corrado, et al.
Publicado: (2021) -
Leucocyte count predicts cardiovascular risk in heart failure with preserved ejection fraction: insights from TOPCAT Americas
por: Bajaj, Navkaranbir S., et al.
Publicado: (2020) -
Associations of Left Ventricular Structure and Function With Blood Pressure in Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
por: Wei, Fang‐Fei, et al.
Publicado: (2020)